WallStreetZenWallStreetZen

NASDAQ: RXRX
Recursion Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for RXRX

Based on 2 analysts offering 12 month price targets for Recursion Pharmaceuticals Inc.
Min Forecast
$12.00+43.54%
Avg Forecast
$14.50+73.44%
Max Forecast
$17.00+103.35%

Should I buy or sell RXRX stock?

Based on 2 analysts offering ratings for Recursion Pharmaceuticals Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RXRX stock forecasts and price targets.

RXRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-07-11
lockedlocked$00.00+00.00%2024-06-25

1 of 1

Forecast return on equity

Is RXRX forecast to generate an efficient return?
Company
-70.31%
Industry
72.87%
Market
62.96%
RXRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RXRX forecast to generate an efficient return on assets?
Company
-50.56%
Industry
29.52%
RXRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RXRX earnings per share forecast

What is RXRX's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.56
Avg 2 year Forecast
-$1.36
Avg 3 year Forecast
-$1.19

RXRX revenue forecast

What is RXRX's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$47.4M+2.61%
Avg 2 year Forecast
$48.9M+5.83%
Avg 3 year Forecast
$80.0M+72.96%
RXRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

RXRX revenue growth forecast

How is RXRX forecast to perform vs Biotechnology companies and vs the US market?
Company
11.4%
Industry
63.45%
Market
9.96%
RXRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RXRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RXRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RXRX$8.36$14.50+73.44%Strong Buy
SNDX$23.48$34.50+46.93%Strong Buy
IMCR$39.51$81.88+107.23%Strong Buy
ARVN$28.87$68.70+137.96%Strong Buy
VERA$36.62$49.80+35.99%Strong Buy

Recursion Pharmaceuticals Stock Forecast FAQ

Is Recursion Pharmaceuticals Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: RXRX) stock is to Strong Buy RXRX stock.

Out of 2 analysts, 1 (50%) are recommending RXRX as a Strong Buy, 1 (50%) are recommending RXRX as a Buy, 0 (0%) are recommending RXRX as a Hold, 0 (0%) are recommending RXRX as a Sell, and 0 (0%) are recommending RXRX as a Strong Sell.

If you're new to stock investing, here's how to buy Recursion Pharmaceuticals stock.

What is RXRX's earnings growth forecast for 2024-2026?

(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.24%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.54%.

Recursion Pharmaceuticals's earnings in 2024 is -$354,112,000.On average, 4 Wall Street analysts forecast RXRX's earnings for 2024 to be -$369,567,004, with the lowest RXRX earnings forecast at -$396,898,326, and the highest RXRX earnings forecast at -$344,612,319. On average, 5 Wall Street analysts forecast RXRX's earnings for 2025 to be -$324,173,243, with the lowest RXRX earnings forecast at -$389,768,416, and the highest RXRX earnings forecast at -$261,430,035.

In 2026, RXRX is forecast to generate -$282,035,475 in earnings, with the lowest earnings forecast at -$320,845,952 and the highest earnings forecast at -$254,300,125.

What is RXRX's revenue growth forecast for 2024-2026?

(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual revenue growth rate of 11.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 63.45%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.96%.

Recursion Pharmaceuticals's revenue in 2024 is $46,235,000.On average, 6 Wall Street analysts forecast RXRX's revenue for 2024 to be $11,275,477,401, with the lowest RXRX revenue forecast at $1,600,189,477, and the highest RXRX revenue forecast at $19,797,383,544. On average, 6 Wall Street analysts forecast RXRX's revenue for 2025 to be $11,628,883,275, with the lowest RXRX revenue forecast at $3,034,965,040, and the highest RXRX revenue forecast at $20,819,337,317.

In 2026, RXRX is forecast to generate $19,005,725,866 in revenue, with the lowest revenue forecast at $2,661,833,082 and the highest revenue forecast at $49,529,108,411.

What is RXRX's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: RXRX) forecast ROA is -50.56%, which is lower than the forecast US Biotechnology industry average of 29.52%.

What is RXRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year RXRX price target, the average RXRX price target is $14.50, with the highest RXRX stock price forecast at $17.00 and the lowest RXRX stock price forecast at $12.00.

On average, Wall Street analysts predict that Recursion Pharmaceuticals's share price could reach $14.50 by Jul 11, 2025. The average Recursion Pharmaceuticals stock price prediction forecasts a potential upside of 73.44% from the current RXRX share price of $8.36.

What is RXRX's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: RXRX) Recursion Pharmaceuticals's current Earnings Per Share (EPS) is -$1.62. On average, analysts forecast that RXRX's EPS will be -$1.56 for 2024, with the lowest EPS forecast at -$1.67, and the highest EPS forecast at -$1.45. On average, analysts forecast that RXRX's EPS will be -$1.36 for 2025, with the lowest EPS forecast at -$1.64, and the highest EPS forecast at -$1.10. In 2026, RXRX's EPS is forecast to hit -$1.19 (min: -$1.35, max: -$1.07).

What is RXRX's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: RXRX) forecast ROE is -70.31%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.